Kymera Therapeutics
Update in progressKYMR (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule degraders that selectively eliminate disease-causing proteins via the body’s natural protein disposal system. Its programs include KT-621, an oral STAT6 degrader in Phase 2b for multiple inflammatory skin and airway diseases; KT-579, an oral IRF5 degrader in Phase 1 for autoimmune conditions; KT-485/SAR447971 (IRAK4) in Phase II; and CDK2 with oncology potential. It has a Sanofi alliance for IRAK4 outside oncology/inflammation. Incorporated 2015, based in Watertown, MA.
Company score
- Sentiment
- 0.44
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Nello Mainolfi M.D., Ph.D.
- Founded2015
- Employees273
- Websitewww.kymeratx.com
Identifiers
- ISINUS5015751044
- FIGIBBG00SDHC8D1
- CUSIP501575104
- CIK0001815442